Abstract
Background This study aimed to describe the population at risk of severe COVID-19 due to underlying health conditions across the United Kingdom in 2019.
Methods We used anonymised electronic health records from the Clinical Practice Research Datalink GOLD to describe the point prevalence on 5 March 2019 of the at-risk population following national guidance. Prevalence for any risk condition and for each individual condition is given overall and stratified by age and region. We repeated the analysis on 5 March 2014 for full regional representation and to describe prevalence of underlying health conditions in pregnancy. We additionally described the population of cancer survivors, and assessed the value of linked secondary care records for ascertaining COVID-19 at-risk status.
Findings On 5 March 2019, 24·4% of the UK population were at risk due to a record of at least one underlying health condition, including 8·3% of school-aged children, 19·6% of working-aged adults, and 66·2% of individuals aged 70 years or more. 7·1% of the population had multimorbidity. The size of the at-risk population was stable over time comparing 2014 to 2019, despite increases in chronic liver disease and diabetes and decreases in chronic kidney disease and current asthma. Separately, 1·6% of the population had a new diagnosis of cancer in the past five years.
Interpretation The population at risk of severe COVID-19 (aged ≥70 years, or with an underlying health condition) comprises 18.5 million individuals in the UK, including a considerable proportion of school-aged and working-aged individuals.
Funding NIHR HPRU in Immunisation
Evidence before this study We searched Pubmed for peer-reviewed articles, preprints, and research reports on the size and distribution of the population at risk of severe COVID. We used the terms (1) risk factor or co-morbidity or similar (2) COVID or SARS or similar and (3) prevalence to search for studies aiming to quantify the COVID-19 at-risk UK population published in the previous year to 19 July 2020, with no language restrictions. We found one study which modelled prevalence of risk factors based on the Global Burden of Disease (which included the UK) and one study which estimated that 8.4 million individuals aged ≥30 years in the UK were at risk based on prevalence of a subset of relevant conditions in England. There were no studies which described the complete COVID-19 at-risk population across the UK.
Added value of this study We used a large, nationally-representative dataset based on electronic health records to estimate prevalence of increased risk of severe COVID-19 across the United Kingdom, including all conditions in national guidance. We stratified by age, sex and region to enable regionally-tailored prediction of COVID-19-related healthcare burden and interventions to reduce transmission of infection, and planning and modelling of vaccination of the at-risk population. We also quantified the value of linked secondary care records to supplement primary care records.
Implications of all the available evidence Individuals at moderate or high risk of severe COVID-19 according to current national guidance (aged ≥70 years, or with a specified underlying health condition) comprise 18·5 million individuals in the United Kingdom, rather than the 8.43 million previously estimated.
The 8·3% of school-aged children and 19·6% of working-aged adults considered at-risk according to national guidance emphasises the need to consider younger at-risk individuals in shielding policies and when re-opening schools and workplaces, but also supports prioritising vaccination based on age and condition-specific mortality risk, rather than targeting all individuals with underlying conditions, who form a large population even among younger age groups.
Among individuals aged ≥70 years, 66·2% had at least one underlying health condition, suggesting an age-targeted approach to vaccination may efficiently target individuals at risk of severe COVID-19.
These national estimates broadly support the use of Global Burden of Disease modelled estimates and age-targeted vaccination strategies in other countries.
Competing Interest Statement
The study was funded by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with Public Health England (PHE). JLW, DJG, NA, JAS, LS, HM received grants from the NIHR HPRU in Immunisation to support the submitted work. RME received grants from HDR UK (MR/S003975/1) and UK MRC (MC_PC 19065). JKQ reports grants and personal fees from AZ, grants from Asthma UK, grants and personal fees from BI, grants and personal fees from Bayer, grants and personal fees from Insmed, grants and personal fees from GSK, grants from The Health Foundation, grants from MRC, grants from British Lung Foundation, outside the submitted work; RM reports personal fees from AMGEN, outside the submitted work; JAS reports grants from National Institute for Health Research, during the conduct of the study; grants from MRC, grants from Wellcome Trust, grants from GAVI The Vaccine Alliance, grants from Bill & Melinda Gates Foundation, outside the submitted work; LS reports grants from Wellcome, grants from MRC, grants from NIHR, grants from GSK, grants from BHF, grants from Diabetes UK, outside the submitted work; and Is a Trustee of the British Heart Foundation. The PHE Immunisation and Countermeasures Department provides vaccine manufacturers with post-marketing surveillance reports which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or PHE.
Clinical Trial
This is not a clinical trial.
Funding Statement
The study was funded by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with Public Health England (PHE). JLW, DJG, NA, JAS, LS, MR and HM received grants from the NIHR HPRU in Immunisation to support the submitted work. RME received grants from HDR UK (MR/S003975/1) and UK MRC (MC_PC 19065). The study funder had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or PHE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was received from the Independent Scientific Advisory Committee of the Medicines and Healthcare Products Regulatory Agency (ISAC number: 20_062A) and the Ethics Committee of the London School of Hygiene and Tropical Medicine (reference 21851).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used for this study were obtained from the Clinical Practice Research Datalink (CPRD). All CPRD data are available via an application to the Independent Scientific Advisory Committee (see https://www.cprd.com/Data-access). Data acquisition is associated with a fee and data protection requirements. This manuscript is supported by shared codelists used to define each condition, and full estimates of the prevalence of the at-risk population and each underlying health condition, stratified by age and region (separately and combined) are provided online.
